Trial reportJournal of cardiovascular electrophysiology2019
Recurrent atrial fibrillation/flutter detection after ablation or cardioversion using the AliveCor KardiaMobile device: iHEART results.
Trial report in Journal of cardiovascular electrophysiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02731326 (iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology), which is not on this map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Artificial Intelligence in the Heart of Medicine: A Systematic Approach to Transforming Arrhythmia Care with Intelligent Systems.Current cardiology reviews · 2025Pooled it
- Guideline
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Impact of Mobile Health Devices for the Detection of Atrial Fibrillation: Systematic Review.JMIR mHealth and uHealth · 2021Pooled it
- Conversational AI Phone Calls to Support Patients With Atrial Fibrillation: Randomized Controlled Trial.JMIR cardio · 2025Trial
- Patient Perspectives on Conversational Artificial Intelligence for Atrial Fibrillation Self-Management: Qualitative Analysis.Journal of medical Internet research · 2025Trial
- Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial.European journal of cardiovascular nursing · 2022Trial
- Ablation Index-guided point-by-point ablation versus Grid annotation-guided dragging for pulmonary vein isolation: A randomized controlled trial.Journal of cardiovascular electrophysiology · 2022Trial
- Recurrent atrial fibrillation/flutter detection after ablation or cardioversion using the AliveCor KardiaMobile device: iHEART results.Journal of cardiovascular electrophysiology · 2019Trial
- Artificial Intelligence Powered Wearable and Portable Devices for Remote Cardiac Care and Population Health.Current cardiology reports · 2026Review
- A Neurosurgeon's Guide to Mobile Health Application Development With a Case Study for Cervical Myelopathy.Neurosurgery · 2026Article
- Contemporary wearable and handheld technology for the diagnosis of cardiac arrhythmias in Singapore.Singapore medical journal · 2026Review
- Patient-Led Smartwatch ECG Follow-Up Strategy After AF Ablation: Clinical Trial Design and Implementation.JACC. Advances · 2026Article
- Monitoring Atrial Fibrillation Using Wearable Digital Technologies: The Emerging Role of Smartwatches.Journal of clinical medicine · 2025Review
- Patient Driven EKG Device Performance in Adults with Fontan Palliation.Pediatric cardiology · 2025Article
- Temporal and spatial self supervised learning methods for electrocardiograms.Scientific reports · 2025Article
- How to Demonstrate the Prognostic Benefit of Aggressive Screening of Atrial FibrillationReply.Arquivos brasileiros de cardiologia · 2025Article
- Wearable Devices for Supporting Chronic Disease Self-Management: Scoping Review.Interactive journal of medical research · 2024Article
- 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.Journal of arrhythmia · 2024Article
- 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveThis study evaluated the impact of daily ECG (electrocardiogram) self-recordings on time to documented recurrent atrial fibrillation (AF) or atrial flutter (AFL) and time to treatment of recurrent arrhythmia in patients undergoing catheter radiofrequency ablation (RFA) or direct current cardioversion (DCCV) for AF/AFL.
backgroundAF recurrence rates after RFA and DCCV are 20% to 45% and 60% to 80%, respectively. Randomized trials comparing mobile ECG devices to standard of care have not been performed in an AF/AFL population after treatment.
methodsOf 262 patients consented, 238 were randomized to either standard of care (123) or to receive the iHEART intervention (115). Patients in the intervention group were provided with and trained to use an AliveCor KardiaMobile ECG monitor, and were instructed to take and transmit daily ECG recordings. Data were collected from transmitted ECG recordings and patients' electronic health records.
resultsIn a multivariate Cox model, the likelihood of recurrence detection was greater in the intervention group (hazard ratio = 1.56, 95% confidence interval [CI]: 1.06-2.30, P = .024). Hazard ratios did not differ significantly for RFA and DCCV procedures. Recurrence during the first month after ablation strongly predicted later recurrence (hazard ratio = 4.53, 95% CI: 2.05-10.00, P = .0006). Time from detection to treatment was shorter for the control group (hazard ratio = 0.33, 95% CI: 0.57-2.92, P < .0001).
conclusionsThe use of mobile ECG self-recording devices allows for earlier detection of AF/AFL recurrence and may empower patients to engage in shared health decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.